Esomeprazole
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Esomeprazole: From Acid-Related Gastrointestinal Disorders to Duodenogastric Reflux
One-Sentence Summary
Esomeprazole is a proton pump inhibitor (PPI) used to suppress gastric acid in acid-related upper gastrointestinal conditions. The TxGNN model predicts it may be effective for duodenogastric reflux (bile reflux), but there are 0 clinical trials and only 1 general review behind this direction, so the evidence is indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the US licence records (approved-indication text is empty). Literature describes PPIs as first-choice drugs for peptic ulcer, GERD and related acid-related conditions |
| Predicted New Indication | Duodenogastric reflux |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 licences (the 5 listed below are all ANDA207193) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the source record. Esomeprazole is known to suppress gastric acid by inhibiting the H+/K+-ATPase (proton pump) in gastric parietal cells. Its efficacy in acid-related upper GI disease is well established.
Duodenogastric reflux is driven by bile and pancreatic secretions flowing back into the stomach, not by acid. Acid suppression may therefore relieve symptoms or mucosal injury from mixed acid-bile exposure, but it does not address the underlying cause.
The very high TxGNN score is probably driven by graph proximity to other upper-GI acid-related conditions rather than a direct mechanistic link. The only supporting item is a general PPI review, which is indirect evidence. The mechanistic link should be treated as weak and unconfirmed.
Clinical Trial Evidence
Currently no related clinical trials registered for duodenogastric reflux.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18679668 | 2008 | Review | Eur J Clin Pharmacol | Update on PPI clinical use and pharmacokinetics. PPIs are first-choice drugs for peptic ulcer, H. pylori infection, GERD, NSAID-induced GI lesions and Zollinger-Ellison syndrome. Duodenogastric reflux is not specifically addressed. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA207193 | dg health esomeprazole magnesium | Capsule, delayed release | Dolgencorp Inc |
| ANDA207193 | up and up esomeprazole magnesium | Capsule, delayed release | Target Corporation |
| ANDA207193 | Esomeprazole Magnesium | Capsule, delayed release | Publix Super Markets Inc |
| ANDA207193 | Esomeprazole Magnesium | Capsule, delayed release | H E B |
| ANDA207193 | Esomeprazole Magnesium | Capsule, delayed release | Walgreen Company |
Other dosage forms on the US market include injection, lyophilized powder for injection, and orally disintegrating delayed-release tablets.
Safety Considerations
Please refer to the package insert for safety information. No drug-interaction records were found in the source data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction relies on model score and a single general PPI review. There are no clinical trials, and acid suppression does not target the bile-driven cause of duodenogastric reflux.
To proceed, the following is needed:
- Literature or trials that directly test PPIs or esomeprazole in duodenogastric (bile) reflux, including symptom and mucosal endpoints
- Detailed mechanism-of-action data and the current US label indications
- Package insert warnings and contraindications for safety screening
- Route compatibility assessment
- A note for context: the third-ranked prediction, duodenal ulcer, has multiple completed Phase 3 trials and RCT literature. It is probably an existing labelled use rather than true repurposing, and it may be the better candidate to evaluate first
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.